Medizinische Hochschule Hannover

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Shashi Kumar Gupta

Thomas Thum

Janika Viereck

Kamal Chowdhury

Ahmet Ucar

Maria-Teresa Piccoli

The present invention relates to a compound inhibiting the expression and/or the activity of maternally expressed 3 (Meg3) for use in treating or preventing cardiac remodelling.

LNCRNA MEG3 for therapy and diagnosis of cardiac remodelling

The present invention refers to inhibitors of microRNAs, particularly of microRNAs miR-212 and/or miR-132 for use in medicine, particularly in the diagnosis, treatment or prevention of cardiac disorders, e.g. cardiac hypertrophy-associated or autophagic disorders, and further refers to isolated nucleic acid molecules, particularly microRNAs miR-212 and/or miR-132 and related sequences, for use in medicine, particularly human medicine, more particularly in the diagnosis, treatment or prevention of disorders involving cardiac atrophy and/or dysfunctional autophagy, e.g. cardiac cachexia.

miRNA-212/132 family as a therapeutic target

Growing community of inventors

Hannover, Germany

Shashi Kumar Gupta